Spago Nanomedical's Q1 report signals steady progress with its radiopharma pipeline. Lead programme Tumorad recently got a boost by the release of positive non-clinical data in a triple-negative breast cancer model, incentivising the company to strengthen its management.

- 2024 has begun in the same positive spirit as we ended last year. Given the progress within both of our development programmes, we have seen a need to strengthen the company's organisation, says Spago's CEO Mats Hansen.